NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

Cell

Volumn 175, Issue 7, 2018, Pages 1744-1755.e15

  van Montfoort, Nadine ^a   Borst, Linda ^a   Korrer, Michael J ^b   Sluijter, Marjolein ^a   Marijt, Koen A ^a   Santegoets, Saskia J ^a   van Ham, Vanessa J ^a   Ehsan, Ilina ^a   Charoentong, Pornpimol ^c   André, Pascale ^d   Wagtmann, Nicolai ^d   Welters, Marij J P ^a   Kim, Young J ^b   Piersma, Sytse J ^e   van der Burg, Sjoerd H ^a   van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d INNATE PHARMA   (France)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acquired resistance; cancer vaccines; CD8 T cells; HLA E; IFN ; immune checkpoints; mouse tumor models; natural killer cells; NKG2A; Qa 1

Indexed keywords

ANTIBODY; CANCER VACCINE; HLA E ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; PROGRAMMED DEATH 1 RECEPTOR; ALPHA E INTEGRINS; ALPHA INTEGRIN; CANCER ANTIBODY; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; LEUKOCYTE ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; TUMOR PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENTIATION; GENE KNOCKDOWN; GENE KNOCKOUT; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; INTEGRIN ALPHA CHAINS; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; VACCINATION;

EID: 85058015117     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.10.028     Document Type: Article

References (57)

1. Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., Mandai, M., IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112 (2015), 1501–1509.
2. Andersson, E., Poschke, I., Villabona, L., Carlson, J.W., Lundqvist, A., Kiessling, R., Seliger, B., Masucci, G.V., Non-classical HLA-class I expression in serous ovarian carcinoma: correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. OncoImmunology, 5, 2015, e1052213.
3. André P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Remark, R., Breso, V., et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175 (2018), 1731–1743 this issue.
4. Anfossi, N., André P., Guia, S., Falk, C.S., Roetynck, S., Stewart, C.A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006), 331–342.
5. Ang, K.K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D.I., Nguyen-Tân, P.F., Westra, W.H., Chung, C.H., Jordan, R.C., Lu, C., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363 (2010), 24–35.
6. Bertone, S., Schiavetti, F., Bellomo, R., Vitale, C., Ponte, M., Moretta, L., Mingari, M.C., Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur. J. Immunol. 29 (1999), 23–29.
7. Bösmüller, H.C., Wagner, P., Peper, J.K., Schuster, H., Pham, D.L., Greif, K., Beschorner, C., Rammensee, H.G., Stevanović S., Fend, F., Staebler, A., Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int. J. Gynecol. Cancer 26 (2016), 671–679.
8. Braud, V.M., Allan, D.S., O'Callaghan, C.A., Söderström, K., D'Andrea, A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.I., Phillips, J.H., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998), 795–799.
9. Braud, V.M., Aldemir, H., Breart, B., Ferlin, W.G., Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells. Trends Immunol. 24 (2003), 162–164.
10. Brooks, A.G., Posch, P.E., Scorzelli, C.J., Borrego, F., Coligan, J.E., NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 185 (1997), 795–800.
11. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517 (2015), 576–582.
12. de Vos van Steenwijk, P.J., Heusinkveld, M., Ramwadhdoebe, T.H., Löwik, M.J., van der Hulst, J.M., Goedemans, R., Piersma, S.J., Kenter, G.G., van der Burg, S.H., An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 70 (2010), 2707–2717.
13. DeCloux, A., Woods, A.S., Cotter, R.J., Soloski, M.J., Forman, J., Dominance of a single peptide bound to the class I(B) molecule, Qa-1b. J. Immunol. 158 (1997), 2183–2191.
14. b with TAP-independent peptides are semi-invariant lymphocytes. Front. Immunol., 9, 2018, 60.
15. Ely, K.H., Matsuoka, M., DeBerge, M.P., Ruby, J.A., Liu, J., Schneider, M.J., Wang, Y., Hahn, Y.S., Enelow, R.I., Tissue-protective effects of NKG2A in immune-mediated clearance of virus infection. PLoS ONE, 9, 2014, e108385.
16. + T lymphocytes. Proc. Natl. Acad. Sci. USA 108 (2011), 10656–10661.
17. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
18. Gunturi, A., Berg, R.E., Crossley, E., Murray, S., Forman, J., The role of TCR stimulation and TGF-beta in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur. J. Immunol. 35 (2005), 766–775.
19. Heusinkveld, M., Goedemans, R., Briet, R.J., Gelderblom, H., Nortier, J.W., Gorter, A., Smit, V.T., Langeveld, A.P., Jansen, J.C., van der Burg, S.H., Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int. J. Cancer 131 (2012), E74–E85.
20. + lung-resident memory T cells. Nat. Immunol. 17 (2016), 1467–1478.
21. Kaiser, B.K., Barahmand-Pour, F., Paulsene, W., Medley, S., Geraghty, D.E., Strong, R.K., Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J. Immunol. 174 (2005), 2878–2884.
22. Klebanoff, C.A., Acquavella, N., Yu, Z., Restifo, N.P., Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 239 (2011), 27–44.
23. Kleinovink, J.W., van Driel, P.B., Snoeks, T.J., Prokopi, N., Fransen, M.F., Cruz, L.J., Mezzanotte, L., Chan, A., Löwik, C.W., Ossendorp, F., Combination of photodynamic therapy and specific immunotherapy efficiently eradicates established tumors. Clin. Cancer Res. 22 (2016), 1459–1468.
24. Komdeur, F.L., Prins, T.M., van de Wall, S., Plat, A., Wisman, G.B.A., Hollema, H., Daemen, T., Church, D.N., de Bruyn, M., Nijman, H.W., CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology, 6, 2017, e1338230.
25. Kraft, J.R., Vance, R.E., Pohl, J., Martin, A.M., Raulet, D.H., Jensen, P.E., Analysis of Qa-1(b) peptide binding specificity and the capacity of CD94/NKG2A to discriminate between Qa-1-peptide complexes. J. Exp. Med. 192 (2000), 613–624.
26. Le Dréan, E., Vély, F., Olcese, L., Cambiaggi, A., Guia, S., Krystal, G., Gervois, N., Moretta, A., Jotereau, F., Vivier, E., Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 28 (1998), 264–276.
27. Ly, L.V., Sluijter, M., Versluis, M., Luyten, G.P., van Stipdonk, M.J., van der Burg, S.H., Melief, C.J., Jager, M.J., van Hall, T., Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res. 70 (2010), 8339–8346.
28. Ly, L.V., Sluijter, M., van der Burg, S.H., Jager, M.J., van Hall, T., Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J. Immunol. 190 (2013), 489–496.
29. Malmberg, K.J., Levitsky, V., Norell, H., de Matos, C.T., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., Kiessling, R., IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110 (2002), 1515–1523.
30. Melief, C.J., van Hall, T., Arens, R., Ossendorp, F., van der Burg, S.H., Therapeutic cancer vaccines. J. Clin. Invest. 125 (2015), 3401–3412.
31. Moser, J.M., Gibbs, J., Jensen, P.E., Lukacher, A.E., CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. Nat. Immunol. 3 (2002), 189–195.
32. O'Callaghan, C.A., Tormo, J., Willcox, B.E., Braud, V.M., Jakobsen, B.K., Stuart, D.I., McMichael, A.J., Bell, J.I., Jones, E.Y., Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol. Cell 1 (1998), 531–541.
33. Ossendorp, F., Mengedé E., Camps, M., Filius, R., Melief, C.J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187 (1998), 693–702.
34. Overwijk, W.W., Theoret, M.R., Finkelstein, S.E., Surman, D.R., de Jong, L.A., Vyth-Dreese, F.A., Dellemijn, T.A., Antony, P.A., Spiess, P.J., Palmer, D.C., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198 (2003), 569–580.
35. + cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci. Immunol., 3, 2018, eaan8664.
36. Piersma, S.J., Welters, M.J., van der Hulst, J.M., Kloth, J.N., Kwappenberg, K.M., Trimbos, B.J., Melief, C.J., Hellebrekers, B.W., Fleuren, G.J., Kenter, G.G., et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int. J. Cancer 122 (2008), 486–494.
37. + T cells in response to a lethal poxvirus infection. Immunity 43 (2015), 1112–1124.
38. Seliger, B., Jasinski-Bergner, S., Quandt, D., Stoehr, C., Bukur, J., Wach, S., Legal, W., Taubert, H., Wullich, B., Hartmann, A., HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget 7 (2016), 67360–67372.
39. Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Ribas, A., Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168 (2017), 707–723.
40. Sheu, B.C., Chiou, S.H., Lin, H.H., Chow, S.N., Huang, S.C., Ho, H.N., Hsu, S.M., Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res. 65 (2005), 2921–2929.
41. Silva, T.G., Crispim, J.C., Miranda, F.A., Hassumi, M.K., de Mello, J.M., Simões, R.T., Souto, F., Soares, E.G., Donadi, E.A., Soares, C.P., Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol. Histopathol. 26 (2011), 1487–1497.
42. Snyder, C.M., Cho, K.S., Bonnett, E.L., van Dommelen, S., Shellam, G.R., Hill, A.B., Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 29 (2008), 650–659.
43. Talebian Yazdi, M., van Riet, S., van Schadewijk, A., Fiocco, M., van Hall, T., Taube, C., Hiemstra, P.S., van der Burg, S.H., The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget 7 (2016), 3477–3488.
44. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
45. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
46. van der Burg, S.H., Arens, R., Ossendorp, F., van Hall, T., Melief, C.J., Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 16 (2016), 219–233.
47. van der Sluis, T.C., Sluijter, M., van Duikeren, S., West, B.L., Melief, C.J., Arens, R., van der Burg, S.H., van Hall, T., Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol. Res. 3 (2015), 1042–1051.
48. van Esch, E.M., Tummers, B., Baartmans, V., Osse, E.M., Ter Haar, N., Trietsch, M.D., Hellebrekers, B.W., Holleboom, C.A., Nagel, H.T., Tan, L.T., et al. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int. J. Cancer 135 (2014), 830–842.
49. van Esch, E.M., van Poelgeest, M.I., Kouwenberg, S., Osse, E.M., Trimbos, J.B., Fleuren, G.J., Jordanova, E.S., van der Burg, S.H., Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. Int. J. Cancer 136 (2015), E95–E106.
50. Vance, R.E., Jamieson, A.M., Raulet, D.H., Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J. Exp. Med. 190 (1999), 1801–1812.
51. Wang, Z.Q., Milne, K., Derocher, H., Webb, J.R., Nelson, B.H., Watson, P.H., CD103 and intratumoral immune response in breast cancer. Clin. Cancer Res. 22 (2016), 6290–6297.
52. + tumor-infiltrating lymphocytes in ovarian cancer. OncoImmunology, 3, 2014, e27668.
53. Webb, J.R., Milne, K., Watson, P., Deleeuw, R.J., Nelson, B.H., Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20 (2014), 434–444.
54. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe'er, D., Allison, J.P., Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (2017), 1120–1133.
55. Welters, M.J.P., Ma, W., Santegoets, S.J., Goedemans, R., Ehsan, I., Jordanova, E.S., van Ham, V.J., van Unen, V., Koning, F., van Egmond, S.I., et al. Intratumoral HPV16-specific T-cells constitute a type 1 oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin. Cancer Res. 24 (2018), 634–647.
56. Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515 (2014), 572–576.
57. Zhou, J., Matsuoka, M., Cantor, H., Homer, R., Enelow, R.I., Cutting edge: engagement of NKG2A on CD8+ effector T cells limits immunopathology in influenza pneumonia. J. Immunol. 180 (2008), 25–29.